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Abstract
Active reabsorption of magnesium (Mg2+) in the distal convoluted tubule
(DCT) of the kidney is crucial for maintaining Mg2+ homeostasis. Impaired
activity of the Na+-Cl-cotransporter (NCC) has been associated with hyper-
magnesiuria and hypomagnesemia, while increased activity of NCC, as
observed in patients with Gordon syndrome, is not associated with alterations
in Mg2+ balance. To further elucidate the possible interrelationship between
NCC activity and renal Mg2+ handling, plasma Mg2+ levels and urinary excre-
tion of sodium (Na+) and Mg2+ were measured in a mouse model of Gordon
syndrome. In this model, DCT1-specific expression of a constitutively active
mutant form of the NCC-phosphorylating kinase, SPAK (CA-SPAK), increases
NCC activity and hydrochlorothiazide (HCTZ)-sensitive Na+ reabsorption.
These mice were normomagnesemic and HCTZ administration comparably
reduced plasma Mg2+ levels in CA-SPAK mice and control littermates. As
inferred by the initial response to HCTZ, CA-SPAK mice exhibited greater
NCC-dependent Na+ reabsorption together with decreased Mg2+ reabsorption,
compared to controls. Following prolonged HCTZ administration (4 days),
CA-SPAK mice exhibited higher urinary Mg2+ excretion, while urinary Na+
excretion decreased to levels observed in control animals. Surprisingly, CA-
SPAK mice had unaltered renal expression of Trpm6, encoding the Mg2+-
permeable channel TRPM6, or other magnesiotropic genes. In conclusion,
CA-SPAK mice exhibit normomagnesemia, despite increased NCC activity
and Na+ reabsorption. Thus, Mg2+ reabsorption is not coupled to increased
thiazide-sensitive Na+ reabsorption, suggesting a similar process explains nor-
momagnesemia in Gordon syndrome. Further research is required to unravel
the molecular underpinnings of this phenomenon and the more pronounced
Mg2+ excretion after prolonged HCTZ administration.
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Introduction
Serum magnesium (Mg2+) levels are kept within physio-
logical range through the combined effects of intestinal
uptake, storage in bone and urinary excretion by the kid-
ney. Defects in either one of these components may result
in hypomagnesemia (i.e., serum Mg2+ levels below
0.7 mmol/L) or hypermagnesemia (i.e., serum Mg2+ levels
above 1.1 mmol/L) (de Baaij et al. 2015).
In the kidney, 70% of Mg2+ is freely filtered by the
glomerulus and then selectively reabsorbed by different
tubule segments along the nephron. The majority of
Mg2+ reabsorption takes place in the proximal tubule and
the thick ascending limb of Henle’s loop, but the fine-
tuning occurs in the distal convoluted tubule (DCT) (de
Baaij et al. 2015). The DCT reabsorbs Mg2+ from the
pro-urine through the apically located Mg2+ channel tran-
sient receptor potential melastatin type 6 (TRMP6),
which is regulated at the level of transcription, plasma
membrane abundance and activity (van der Wijst et al.
2014). In contrast to the well-known apical site of entry,
the basolateral mechanism of Mg2+ extrusion in the DCT
remains largely unknown. Several candidate transporters
have been postulated, including cyclin M2 (CNNM2)
(Stuiver et al. 2011; Arjona et al. 2014) as well as solute
carrier family 41 member 1 (SLC41A1) (Kolisek et al.
2012) and member 3 (SLC41A3) (de Baaij et al. 2016),
but especially the role of SLC41A3 and CNNM2 as baso-
lateral Mg2+ transporters remains controversial (Mastro-
totaro et al. 2016; Sponder et al. 2016).
The DCT is also an important site for sodium (Na+)
reabsorption. Here, Na+ is reabsorbed through the api-
cally located Na+-Cl-cotransporter (NCC). The activity
of this transporter, which facilitates electroneutral trans-
port of Na+ and chloride (Cl), is regulated through
phosphorylation by the with-no-lysine kinase (WNK; i.e.,
WNK1 and WNK4)-Ste20p-related proline- and alanine-
rich kinase (SPAK) pathway (Richardson et al. 2008;
Gamba 2012). Patients with loss-of-function mutations in
the NCC-encoding gene SLC12A3 suffer from Gitelman
syndrome (OMIM 263800) characterized by hypokalemia
and hypomagnesemia (Gitelman et al. 1966; Simon et al.
1996). Pharmacological inhibition of NCC by long-term
treatment with thiazide diuretics, used to treat hyperten-
sion, is also associated with hypomagnesemia (Hollifield
1986; Davies and Fraser 1993; de Baaij et al. 2015). In
addition, both SPAK/ and NCC/ mice develop
hypomagnesemia (Schultheis et al. 1998; Yang et al.
2010; McCormick et al. 2011; Grimm et al. 2015; Verouti
et al. 2015). These observations have led to the well-
accepted idea that Mg2+ reabsorption in the DCT is
dependent on the activity of NCC and thiazide-sensitive
Na+ reabsorption.
However, increased NCC activity may not always be
associated with increased Mg2+ reabsorption. In one
human study, for example, NCC hyperactivity was not
associated with hypermagnesemia (Mayan et al. 2002). A
small number of patients with WNK4 mutations and
Gordon syndrome (pseudohypoaldosteronism type II or
familial hyperkalemic hypertension; OMIM 614491) who
exhibited the classic signs of the disease (hypertension
and hyperkalemia due to an increased activity of NCC
(Gordon et al. 1970; Yang et al. 2003)), did not exhibit
alterations in urinary or plasma Mg2+ (Mayan et al.
2002). Of note, this study only looked at eight unaffected
and eight affected individuals within one family. Larger
studies assessing plasma Mg2+ levels in patients with Gor-
don syndrome have currently not been performed.
To study the relationship between hyperactivation of
NCC and renal Mg2+ handling, we investigated a mouse
model of Gordon syndrome. This model was created by
targeted DCT1-specific knock-in of constitutively active
SPAK (CA-SPAK) through phosphomimetic mutations at
the key activation sites (T243E and S383D) (Grimm et al.
2017). These mice are characterized by NCC hyperactivity
leading to hypertension and hyperkalemia, thus resem-
bling the phenotype of patients with Gordon syndrome.
The CA-SPAK mouse model was used to determine uri-
nary Mg2+ excretion and plasma Mg2+ concentrations, as
well as gene expression of known magnesiotropic genes.
Materials and Methods
Animals and sample collection
The generation of the CA-SPAK mice has been described
previously (Grimm et al. 2017). In short, full length N-
terminal HA-epitope SPAK cDNA bearing two mutations,
T243E and S383D, which render the kinase constitutively
active (Gagnon and Delpire 2010), was inserted after a
floxed neomycin resistance gene cassette into the SPAK
(STK39) gene. Successful insertion of construct creates a
SPAK KO and allows CA-SPAK to be expressed under
control of the native SPAK promoter following recombi-
nation with Cre-recombinase. To drive early DCT
(DCT1)-specific expression within the kidney, male mice
homozygous for floxed CA-SPAK were bred with female
mice that express Cre recombinase under the control of
the parvalbumin promoter (The Jackson Laboratory,
B6.129P2-Pvalbtm1(Cre)Arbr/J). DCT1-specific CA-SPAK
(Parv-Cre/CA-SPAK) (n = 14) and control mice, express-
ing the parvalbumin Cre-driver alone (n = 14), had ad li-
bitum access to water and food. Mice were treated with
an intraperitoneal (i.p.) injection of either hydrochloroth-
iazide (HCTZ; 25 mg/kg/ per day) or vehicle, once daily
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for 4 days. Subsequently, all mice were anesthetized by an
i.p. injection consisting of 100 mg/kg ketamine and
10 mg/kg xylazine and their kidneys were collected. The
cortex was subsequently isolated and stored in RNAlater
(Qiagen GmbH, Hilden, Germany). Twenty-four hour
urine was collected at baseline and during each day of
treatment. Blood samples were drawn from the carotid
artery on day 4 after administration and immediately
spun down to isolate the plasma. All animal experiments
were performed in adherence to the NIH Guide for the
Care and Use of Laboratory Animals and approved by the
University of Maryland School of Medicine Institutional
Animal Care and Use Committee.
RNA isolation, cDNA synthesis, and qPCR
RNA was isolated from the cortex using an RNeasy Mini
Kit (Qiagen GmbH, Hilden, Germany). RNA integrity was
determined at the Core Facility of the University of Mary-
land School of Medicine using the RNA Integrity Number
(RIN) method (Schroeder et al. 2006). Only samples with
a RIN above 7.5 were deemed eligible. Subsequent cDNA
synthesis was performed using SuperScriptTM III Reverse
Transcriptase (Thermo Fischer Scientific, Carlsbad, CA).
Primer sequences of Cnnm2, Fxyd2, Hnf1b, Slc41a1,
Slc41a3, Trpm6, and Gapdh are shown in Table 1 and were
generated using MacVector version 7.2 (MacVector, Inc.,
Apex, NC). qPCR was performed using a Roche LightCy-
cler 480 qPCR system (Roche Diagnostics GmbH, Man-
nheim, Germany) and LightCycler 480 SYBR Green I
Master reagents (Roche Diagnostics GmbH, Mannheim,
Germany). The analysis was performed using the 2DDCt
approach, using Gapdh transcript abundance for normal-
ization and vehicle-treated control littermates as the con-
trol group (Livak and Schmittgen 2001).
Urinary and plasma electrolyte
measurements
Plasma and urinary samples were sent to IDEXX Preclini-
cal Research Laboratories (Westbrook, ME) for analysis of
plasma and urinary Mg2+ concentrations, as well as uri-
nary concentrations of Na+. The 24-h urinary Mg2+ and
Na+ excretion was calculated using 24-hour urine volume.
Statistical analyses
All data are presented as mean  SEM. Student’s inde-
pendent t-test was used for statistical comparison; a
P < 0.05 was considered statistically significant. All statis-
tical analyses were performed using Graphpad Prism 5.0
(Graphpad Software). All experiments were performed in
a blinded manner and unblinding occurred immediately
before statistical analysis.
Results
CA-SPAK mice exhibit normomagnesemia
and no coupling of Mg2+ and Na+
reabsorption
To determine whether CA-SPAK mice exhibit an altered
steady-state Mg2+ balance, plasma Mg2+ levels were deter-
mined. The CA-SPAK mice had similar plasma Mg2+
levels as control mice (Fig. 1). Prolonged administration
of HCTZ (4 days) induced hypomagnesemia in both
groups, but there was no difference in response between
the genotypes. To further investigate the observed normo-
magnesemia in CA-SPAK mice, urinary Na+ and Mg2+
excretion was analyzed. No statistically significant differ-
ences were present in urinary Na+ or Mg2+ excretion at
baseline, within or between genotypes (Table 2). As
expected, and in concordance with a previous study
(Grimm et al. 2017), CA-SPAK mice showed higher
HCTZ-dependent Na+-reabsorption compared to their
control littermates, as indicated by a higher Na+ excretion
following HCTZ treatment (Fig. 2A). Surprisingly, an
opposite effect was observed on the Mg2+ excretion of
CA-SPAK mice (Fig. 2B). In fact, at the initial HCTZ
response (day 1), Mg2+ excretion was significantly lower
in CA-SPAK mice (Fig. 2C), indicating that NCC- and/or
SPAK-dependent Mg2+ reabsorption is suppressed. Only
Table 1. Primer sequences used for gene expression analysis by qPCR.
Gene Forward primer Reverse primer
Trpm6 50-AAAGCCATGCGAGTTATCAGC-30 50-CTTCACAATGAAAACCTGCCC-30
Cnnm2 50-AAGCACCCCAATGTCATCCAG-30 50-CATCACACCATAGTAGGAGAAAGCG-30
Hnf1b 50-GGCAAAAGAATCCCAGCAAGG-30 50-GAACCAGTTGTAGACACGGACCTC-30
Fxyd2 50-AGTGCCAAGGGGACAGAGAATC-30 50-CAGTTCCATCTTCATTGACCTGCC-30
Slc41a1 50-AAGTGCTGTTCCCCTTCCTACTG-30 50-CTGGGAACTCTACAGAAAAAGGGAG-30
Slc41a3 50-GCACGAGTCCTGCTCTTTCT-30 50-CACTTCTGCCAGGTACAGCA-30
Gapdh 50-TGATGGGTGTGAACCACGAG-30 50-GGCATGGACTGTGGTCATGA-30
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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until after longer treatment with HCTZ (4 days), did the
CA-SPAK mice display a significantly higher urinary
Mg2+ excretion than control mice (Fig. 2B and D),
consistent with indirect effects of HCTZ and/or NCC
inhibition.
Expression of magnesiotropic genes
To explore the underlying mechanism of Mg2+ excretion
in CA-SPAK mice, the expression of genes known to be
involved in Mg2+ reabsorption in the DCT was analyzed
by qPCR. These include transcripts of Trpm6, transcrip-
tion factor Hnf1b and Fxyd2, Slc41a1, Slc41a3, and
Cnnm2.
The expression of these genes was compared between
the vehicle-treated control animals group and the vehicle-
treated CA-SPAK group to determine whether CA-SPAK
mice have differential gene expression as a result of the
constitutive SPAK signaling and NCC hyperactivity. No
significant differences were present for renal expression of
Trpm6, Fxyd2, Slc41a1, Slc41a3, Hnf1b, or Cnnm2
(Fig. 3A–F). In addition, gene expression of the same
genes was compared between HCTZ-treated CA-SPAK
mice and control mice to investigate the higher Mg2+
excretion following chronic thiazide administration in
CA-SPAK mice. Expression of Trpm6 was significantly
higher in the 4 day HCTZ-treated CA-SPAK mice than in
the HCTZ-treated controls even though Mg2+ excretion
was greater in the CA-SPAK mice at this time point. In
contrast, no significant differences were present for the
other genes (Fig. 3A–F).
Discussion
It is well established that decreased NCC activity is associ-
ated with urinary Mg2+ wasting and hypomagnesemia
(e.g., Gitelman syndrome and chronic treatment with thi-
azide diuretics). This indicates that NCC-dependent Na+
reabsorption is required for Mg2+ reabsorption in the
DCT. Indeed, this notion is supported by the observation
that SPAK/ mice, which lack the kinase responsible for
phosphorylating NCC, also develop hypomagnesemia and
renal Mg2+ wasting (Yang et al. 2010; McCormick et al.
2011; Grimm et al. 2015). However, patients with NCC
hyperactivity (e.g., Gordon syndrome) are reported to be
normomagnesemic and normomagnesiuric (Wilson et al.
2001; Mayan et al. 2002). Using a mouse model of Gor-
don syndrome, our study confirmed the normomagne-
semic phenotype and revealed that this is due to the fact
that thiazide-sensitive Na+ reabsorption is not coupled to
Mg2+ reabsorption. As estimated by the initial urinary
response to HCTZ, we found NCC-dependent Mg2+ reab-
sorption is actually suppressed in the CA-SPAK mice,
despite increased NCC activity. We speculate that
enhanced Mg2+ reabsorption in other segments offsets the
decrease in DCT-specific Mg2+ reabsorption to maintain
normal Mg2+ balance.
Since we did not observe any significant differences in
the mRNA expression of magnesiotropic genes between
control mice and CA-SPAK mice under control condi-
tions, we speculate that post-transcriptional modifications
are responsible for opposite responses on Na+ and Mg2+
reabsorption in CA-SPAK mice. It is possible, for exam-
ple, that constitutive SPAK signaling directly inhibits
TRPM6, the apical Mg2+ channel responsible for Mg2+
reabsorption in the DCT. Technically demanding patch-
clamp experiments, in vivo or in vitro, on TRPM6 will be
required to test this idea. In addition, the activities of
other magnesiotropic proteins might also be contributory.
Because SPAK is the terminal kinase in the WNK sig-
naling pathway that is altered in Gordon syndrome, our
results should be broadly applicable to the disease. Never-
theless, it will be important to determine whether Mg2+
homeostasis is altered as a direct result of CA-SPAK and
whether a WNK4 mouse model of Gordon syndrome
exhibits the same phenotype (Wilson et al. 2001). Inter-
estingly, a WNK1 mouse model of Gordon syndrome,
characterized by deletion of the first exon of Wnk1,
reported normal plasma Mg2+ levels and urinary Mg2+
excretion (Vidal-Petiot et al. 2013). A recent study by
Terker et al. (2018) showed that WNK4 is involved in
phosphorylation of the Na-K-Cl cotransporter 2
(NKCC2). Moreover, it was also shown that a WNK4-
Q562E mouse model of Gordon syndrome exhibited
increased phosphorylated NKCC2 levels, which explained
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Figure 1. Plasma Mg2+ concentration for each group (n = 3).
Blood samples were collected on the final day of either vehicle or
HCTZ treatment for 4 days. Data are presented as mean  SEM.
*P < 0.05 versus vehicle-treated group of the respective genotype.
2018 | Vol. 6 | Iss. 14 | e13728
Page 4
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Gordon Syndrome: No Coupled Na+-Mg2+ Reabsorption W. H. van Megen et al.
the normocalciuria in these mice. Since increased NKCC2
activity could lead to a more favorable electrical gradient
for paracellular Mg2+ reabsorption (de Baaij et al. 2015),
combined alterations in the Mg2+ handling in TAL and
DCT may explain the normomagnesemia and normomag-
nesiuria in patients with Gordon syndrome.
Table 2. Urinary Na+ and Mg2+ excretion at baseline and after treatment for each group (n = 7). Values are presented as mean  SEM.
Electrolyte Mice group
Vehicle (lmol/24 h) HCTZ (lmol/24 h)
Day 0 Day 4 Day 0 Day 4
Na+ Control 269.0  15.3 275.7  15.9 272.8  18.4 425.5  24.7
CA-SPAK 250.4  6.6 277.7  18.2 256.4  11.2 448.4  21.9
Mg2+ Control 27.2  1.0 29.5  1.7 29.5  1.0 65.0  1.4
CA-SPAK 27.2  1.9 25.7  0.7 26.9  1.3 82.0  2.1
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Figure 2. Change in urinary excretion of Na+ and Mg2+ in CA-SPAK mice and control littermates after HCTZ treatment (n = 7 per group).
Urine was collected on every day of HCTZ treatment. Data are presented as mean  SEM and were calculated by subtracting Na+ and Mg2+
excretion values following HCTZ treatment with the excretion values of Na+ and Mg2+ at baseline, respectively. (A) HCTZ-sensitive Na+ excretion
and (B) HCTZ-sensitive Mg2+ excretion is shown for control and CA-SPAK mice. (C) Acute HCTZ-sensitive Mg2+ excretion during peak HCTZ
response (day 1). (D) Prolonged HCTZ-sensitive Mg2+ excretion for both genotypes on day 4 of HCTZ treatment. * indicates P < 0.05 compared
to HCTZ-treated control mice.
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It is also important to consider that the DCT1-specific
CA-SPAK mice are engineered on a SPAK null back-
ground. Thus, when NCC is inhibited, these mice revert
to a SPAK null phenotype. We (Grimm et al. 2015) and
others (Yang et al. 2010; McCormick et al. 2011) have
found that SPAK knockout mice exhibit a phenotype like
Gitelman patients, who lack functional NCC (Gitelman
et al. 1966; Simon et al. 1996), characterized by salt-wast-
ing, hypokalemia, and urinary Mg2+ wasting. The specific
genetic background of CA-SPAK mice could also have
implications for renal Mg2+ handling in the thick ascend-
ing limb of Henle’s loop given the data suggesting a role
for SPAK in NKCC2 function (Moriguchi et al. 2005;
Cheng et al. 2015). This may explain why CA-SPAK mice
excrete significantly more Mg2+ than control animals after
prolonged HCTZ treatment. However, in contrast to
NCC knockout mice and chronic HCTZ administration
in wild-type mice, which exhibit downregulation of Trp-
m6 (Nijenhuis et al. 2005, we found Trpm6 RNA levels
are not affected in CA-SPAK mice by prolonged HCTZ
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Figure 3. mRNA expression of known magnesiotropic genes expressed in the kidney as measured by qPCR. All measurements were performed
after 4 days of thiazide or vehicle treatment. mRNA expression is shown relative to control littermates treated with vehicle and normalized
using Gapdh expression for Trpm6 (A), Cnnm2 (B), Hnf1b (C), Fxyd2 (D), Slc41a1 (E), and Slc41a3 (F). Data are presented as mean  SEM.
*indicates P < 0.05 compared to HCTZ-treated control mice. n = 6 for vehicle-treated control mice, n = 6 for vehicle-treated CA-SPAK mice,
n = 7 for HCTZ-treated control mice, and n = 5 for HCTZ-treated CA-SPAK mice.
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treatment. Thus, high levels of urinary Mg2+ excretion in
the thiazide-treated CA-SPAK mice cannot be attributed
to changes in Trpm6 expression. We speculate that
HCTZ-induced atrophy of the DCT might be more pro-
nounced in CA-SPAK mice. This warrants additional
experiments into alterations in tubular morphology fol-
lowing prolonged HCTZ treatment and their association
with Mg2+ reabsorption.
Conclusion
In summary, thiazide-sensitive Na+ and Mg2+ reabsorp-
tion are not coupled in CA-SPAK mice. These mice dis-
play an impaired NCC-dependent Mg2+ reabsorption,
despite constitutive hyperactivation of NCC. Like human
subjects with Gordon syndrome, CA-SPAK mice do not
exhibit an altered Mg2+ balance. We speculate that
enhanced Mg2+ reabsorption in other segments offsets the
decrease in DCT to maintain normal Mg2+ balance. Fur-
ther research is required to define the mechanisms.
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